|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original Article |
1 Research and Development, Finnish Red Cross Blood Service, Helsinki, Finland
2 Biological Engineering Division, Massachusetts Institute of Technology, Cambridge, MA, USA
3 Institute of Signal Processing, Tampere University of Technology, Tampere, Finland
4 Research and Development, Finnish Red Cross Blood Service, Helsinki, Finland; Department of Tissue Typing, Finnish Red Cross Blood Service, Helsinki, Finland
* To whom correspondence should be addressed. E-mail: jukka.partanen{at}bts.redcross.fi.
| Abstract |
|---|
Human cord blood (CB)-derived CD133+ cells carry characteristics of primitive hematopoietic cells and proffer an alternative for CD34+ cells in hematopoietic stem cell (HSC) transplantation. To characterize the CD133+ cell population on genetic level, a global expression analysis of CD133+ cells was performed using oligonucleotide microarrays. CD133+ cells were purified from 4 fresh CB units by immunomagnetic selection. All 4 CD133+ samples showed significant similarity in their gene expression pattern, whereas they differed clearly from the CD133- control samples. In all, 690 transcripts were differentially expressed between CD133+ and CD133- cells. Of these, 393 were increased and 297 were decreased in CD133+ cells. The highest overexpression was noted in genes associated with metabolism, cellular physiological processes, cell communication and development. A set of 257 transcripts expressed solely in the CD133+ cell population was identified. Colony-forming unit (CFU) assay was used to detect the clonal progeny of precursors present in the studied cell populations. The results demonstrate that CD133+ cells express primitive markers and they possess clonogenic progenitor capacity. This study provides a gene expression profile for human CD133+ cells. It presents a set of genes that may be utilized to unravel the properties of the CD133+ cell population, assumed to be highly enriched in HSCs.
This article has been cited by other articles:
![]() |
C. Langer, M. D. Radmacher, A. S. Ruppert, S. P. Whitman, P. Paschka, K. Mrozek, C. D. Baldus, T. Vukosavljevic, C.-G. Liu, M. E. Ross, et al. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study Blood, June 1, 2008; 111(11): 5371 - 5379. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. G. Spector, A. J. Hooten, and J. A. Ross Ontogeny of Gene Expression: A Changing Environment for Malignancy Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1021 - 1023. [Full Text] [PDF] |
||||
![]() |
T.-S. Huang, J.-Y. Hsieh, Y.-H. Wu, C.-H. Jen, Y.-H. Tsuang, S.-H. Chiou, J. Partanen, H. Anderson, T. Jaatinen, Y.-H. Yu, et al. Functional Network Reconstruction Reveals Somatic Stemness Genetic Maps and Dedifferentiation-Like Transcriptome Reprogramming Induced by GATA2 Stem Cells, May 1, 2008; 26(5): 1186 - 1201. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-S. Tsai, S.-M. Hwang, K.-D. Chen, Y.-S. Lee, L.-W. Hsu, Y.-J. Chang, C.-N. Wang, H.-H. Peng, Y.-L. Chang, A.-S. Chao, et al. Functional Network Analysis of the Transcriptomes of Mesenchymal Stem Cells Derived from Amniotic Fluid, Amniotic Membrane, Cord Blood, and Bone Marrow Stem Cells, October 1, 2007; 25(10): 2511 - 2523. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Martin-Rendon, S. J.M. Hale, D. Ryan, D. Baban, S. P. Forde, M. Roubelakis, D. Sweeney, M. Moukayed, A. L. Harris, K. Davies, et al. Transcriptional Profiling of Human Cord Blood CD133+ and Cultured Bone Marrow Mesenchymal Stem Cells in Response to Hypoxia Stem Cells, April 1, 2007; 25(4): 1003 - 1012. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |
